+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

HIV Vaccines Market Research Report by Antibodies (Dicloxacillin, Fusidic Acid Ointment, and Gentamicin Ointment), Type, Category, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

  • PDF Icon

    Report

  • 249 Pages
  • January 2023
  • Region: Global
  • 360iResearch™
  • ID: 5533222
UP TO OFF until Mar 31st 2023
The Global HIV Vaccines Market size was estimated at USD 487.38 million in 2022, USD 677.83 million in 2023, and is projected to grow at a CAGR of 39.55% to reach USD 7,011.84 million by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the Global HIV Vaccines Market.

Cumulative Impact of Russia-Ukraine Conflict:

The publisher continuously monitors and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the Global HIV Vaccines Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The Global HIV Vaccines Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the Global HIV Vaccines Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. The market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for the market plan. This research report categorizes the Global HIV Vaccines Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Antibodies, the market is studied across Dicloxacillin, Fusidic Acid Ointment, Gentamicin Ointment, and Mupirocin Ointment.
  • Based on Type, the market is studied across Acute Paronychia, Candidal Paronychia, Chronic Paronychia, and Pyogenic Paronychia.
  • Based on Category, the market is studied across Preventive Vaccines and Therapeutic Vaccines.
  • Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the Global HIV Vaccines Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The Global HIV Vaccines Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The Global HIV Vaccines Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The Global HIV Vaccines Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global HIV Vaccines Market, including AlphaVax, Inc., Antigen Express, Inc., Argos Therapeutics, Inc., Bionor Pharmaceuticals, Celldex Therapeutics, Inc., Crucell N.V., GeneCure LLC, Genetic Immunity, Inc., GenVec, Inc., GeoVax Labs, Inc., GlaxoSmithKline plc, Immune Response BioPharma, Inc., Inovio Pharmaceuticals, Inc., Novartis AG, Oncolys Biopharma, Profectus Biosciences, Sanofi SA, and TVAX Biomedical.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global HIV Vaccines Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global HIV Vaccines Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global HIV Vaccines Market?
4. What is the competitive strategic window for opportunities in the Global HIV Vaccines Market?
5. What are the technology trends and regulatory frameworks in the Global HIV Vaccines Market?
6. What is the market share of the leading vendors in the Global HIV Vaccines Market?
7. What modes and strategic moves are considered suitable for entering the Global HIV Vaccines Market?
Frequently Asked Questions about the Global HIV Vaccines Market

What is the estimated value of the Global HIV Vaccines Market?

The Global HIV Vaccines Market was estimated to be valued at $487.38 Million in 2022.

What is the growth rate of the Global HIV Vaccines Market?

The growth rate of the Global HIV Vaccines Market is 39.5%, with an estimated value of $7011.84 Million by 2030.

What is the forecasted size of the Global HIV Vaccines Market?

The Global HIV Vaccines Market is estimated to be worth $7011.84 Million by 2030.

Who are the key companies in the Global HIV Vaccines Market?

Key companies in the Global HIV Vaccines Market include AlphaVax, Inc., Antigen Express, Inc., Argos Therapeutics, Inc., Bionor Pharmaceuticals, Celldex Therapeutics, Inc., Crucell N.V., GeneCure LLC, Genetic Immunity, Inc. and GeoVax Labs, Inc..

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising investments for HIV vaccine production
5.1.1.2. Prevalence of HIV worldwide
5.1.1.3. Increasing awareness due to HIV prevention programs
5.1.2. Restraints
5.1.2.1. Issues related to HIV drug resistance
5.1.3. Opportunities
5.1.3.1. Rising affordability of HIV medicines
5.1.3.2. Increasing R&D activities for HIV vaccines clinical trials
5.1.4. Challenges
5.1.4.1. Limitations of commercialization of HIV vaccine
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization
5.8.1. HIV vaccine construct methodologies
5.8.1.1. Live Attenuated Vaccine
5.8.1.2. Synthetic Peptide Vaccines
5.8.1.3. Inactivated Vaccines
5.8.1.4. DNA Vaccine
5.8.1.5. Recombinant Vector Vaccine
5.8.2. Commercialization of HIV vaccines
5.8.2.1. Controlled Transmission
5.8.2.2. Efficacy
5.8.2.3. Relapse
5.8.2.4. Economical
5.8.2.5. Manufacturing Scalability
5.8.3. HIV vaccine clinical trials
5.8.3.1. Phase I
5.8.3.2. Phase II
5.8.3.3. Phase III
5.8.4. Drug vaccination categorization
5.8.4.1. Nucleoside Analogue Reverse Transcriptase Inhibitors
5.8.4.2. Non-Nucleoside Reverse Transcriptase Inhibitors
5.8.4.3. Protease Inhibitors
5.8.4.4. Fusion Inhibitors

6. HIV Vaccines Market, by Antibodies
6.1. Introduction
6.2. Dicloxacillin
6.3. Fusidic Acid Ointment
6.4. Gentamicin Ointment
6.5. Mupirocin Ointment

7. HIV Vaccines Market, by Type
7.1. Introduction
7.2. Acute Paronychia
7.3. Candidal Paronychia
7.4. Chronic Paronychia
7.5. Pyogenic Paronychia

8. HIV Vaccines Market, by Category
8.1. Introduction
8.2. Preventive Vaccines
8.3. Therapeutic Vaccines

9. Americas HIV Vaccines Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific HIV Vaccines Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa HIV Vaccines Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Product Portfolio Analysis, By Key Player
12.5. Competitive Scenario
12.5.1. Merger & Acquisition
12.5.2. Agreement, Collaboration, & Partnership
12.5.3. New Product Launch & Enhancement
12.5.4. Investment & Funding
12.5.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. AlphaVax, Inc.
13.2. Antigen Express, Inc.
13.3. Argos Therapeutics, Inc.
13.4. Bionor Pharmaceuticals
13.5. Celldex Therapeutics, Inc.
13.6. Crucell N.V.
13.7. GeneCure LLC
13.8. Genetic Immunity, Inc.
13.9. GenVec, Inc.
13.10. GeoVax Labs, Inc.
13.11. GlaxoSmithKline plc
13.12. Immune Response BioPharma, Inc.
13.13. Inovio Pharmaceuticals, Inc.
13.14. Novartis AG
13.15. Oncolys Biopharma
13.16. Profectus Biosciences
13.17. Sanofi SA
13.18. TVAX Biomedical

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL HIV VACCINES MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL HIV VACCINES MARKET SIZE, 2022 VS 2030
FIGURE 3. GLOBAL HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL HIV VACCINES MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2030
FIGURE 7. GLOBAL HIV VACCINES MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 8. GLOBAL HIV VACCINES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HIV VACCINES MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 10. GLOBAL HIV VACCINES MARKET DYNAMICS
FIGURE 11. GLOBAL HIV VACCINES MARKET PORTER’S FIVE FORCES ANALYSIS
FIGURE 12. GLOBAL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2022 VS 2030 (%)
FIGURE 13. GLOBAL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL HIV VACCINES MARKET COMPETITIVE STRATEGIC WINDOW, BY ANTIBODIES, 2030
FIGURE 15. GLOBAL HIV VACCINES MARKET SIZE, BY DICLOXACILLIN, 2018-2030 (USD MILLION)
FIGURE 16. GLOBAL HIV VACCINES MARKET SIZE, BY FUSIDIC ACID OINTMENT, 2018-2030 (USD MILLION)
FIGURE 17. GLOBAL HIV VACCINES MARKET SIZE, BY GENTAMICIN OINTMENT, 2018-2030 (USD MILLION)
FIGURE 18. GLOBAL HIV VACCINES MARKET SIZE, BY MUPIROCIN OINTMENT, 2018-2030 (USD MILLION)
FIGURE 19. GLOBAL HIV VACCINES MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
FIGURE 20. GLOBAL HIV VACCINES MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL HIV VACCINES MARKET COMPETITIVE STRATEGIC WINDOW, BY TYPE, 2030
FIGURE 22. GLOBAL HIV VACCINES MARKET SIZE, BY ACUTE PARONYCHIA, 2018-2030 (USD MILLION)
FIGURE 23. GLOBAL HIV VACCINES MARKET SIZE, BY CANDIDAL PARONYCHIA, 2018-2030 (USD MILLION)
FIGURE 24. GLOBAL HIV VACCINES MARKET SIZE, BY CHRONIC PARONYCHIA, 2018-2030 (USD MILLION)
FIGURE 25. GLOBAL HIV VACCINES MARKET SIZE, BY PYOGENIC PARONYCHIA, 2018-2030 (USD MILLION)
FIGURE 26. GLOBAL HIV VACCINES MARKET SIZE, BY CATEGORY, 2022 VS 2030 (%)
FIGURE 27. GLOBAL HIV VACCINES MARKET SIZE, BY CATEGORY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 28. GLOBAL HIV VACCINES MARKET COMPETITIVE STRATEGIC WINDOW, BY CATEGORY, 2030
FIGURE 29. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE VACCINES, 2018-2030 (USD MILLION)
FIGURE 30. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC VACCINES, 2018-2030 (USD MILLION)
FIGURE 31. AMERICAS HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 32. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 33. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 34. AMERICAS HIV VACCINES MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 35. ARGENTINA HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 36. BRAZIL HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 37. CANADA HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 38. MEXICO HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 39. UNITED STATES HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 40. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 41. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 42. UNITED STATES HIV VACCINES MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 43. ASIA-PACIFIC HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 44. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 45. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 46. ASIA-PACIFIC HIV VACCINES MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 47. AUSTRALIA HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 48. CHINA HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 49. INDIA HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 50. INDONESIA HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 51. JAPAN HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 52. MALAYSIA HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 53. PHILIPPINES HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 54. SINGAPORE HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 55. SOUTH KOREA HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 56. TAIWAN HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 57. THAILAND HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 58. VIETNAM HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 59. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 60. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 61. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 62. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 63. DENMARK HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 64. EGYPT HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 65. FINLAND HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 66. FRANCE HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 67. GERMANY HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 68. ISRAEL HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 69. ITALY HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 70. NETHERLANDS HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 71. NIGERIA HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 72. NORWAY HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 73. POLAND HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 74. QATAR HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 75. RUSSIA HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 76. SAUDI ARABIA HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 77. SOUTH AFRICA HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 78. SPAIN HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 79. SWEDEN HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 80. SWITZERLAND HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 81. TURKEY HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 82. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 83. UNITED KINGDOM HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 84. GLOBAL HIV VACCINES MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 85. GLOBAL HIV VACCINES MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 86. GLOBAL HIV VACCINES MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022


List of Tables
TABLE 1. GLOBAL HIV VACCINES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. GLOBAL HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL HIV VACCINES MARKET SIZE, BY DICLOXACILLIN, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL HIV VACCINES MARKET SIZE, BY DICLOXACILLIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL HIV VACCINES MARKET SIZE, BY DICLOXACILLIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL HIV VACCINES MARKET SIZE, BY FUSIDIC ACID OINTMENT, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL HIV VACCINES MARKET SIZE, BY FUSIDIC ACID OINTMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL HIV VACCINES MARKET SIZE, BY FUSIDIC ACID OINTMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL HIV VACCINES MARKET SIZE, BY GENTAMICIN OINTMENT, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL HIV VACCINES MARKET SIZE, BY GENTAMICIN OINTMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL HIV VACCINES MARKET SIZE, BY GENTAMICIN OINTMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL HIV VACCINES MARKET SIZE, BY MUPIROCIN OINTMENT, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL HIV VACCINES MARKET SIZE, BY MUPIROCIN OINTMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL HIV VACCINES MARKET SIZE, BY MUPIROCIN OINTMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL HIV VACCINES MARKET SIZE, BY ACUTE PARONYCHIA, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL HIV VACCINES MARKET SIZE, BY ACUTE PARONYCHIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL HIV VACCINES MARKET SIZE, BY ACUTE PARONYCHIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL HIV VACCINES MARKET SIZE, BY CANDIDAL PARONYCHIA, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL HIV VACCINES MARKET SIZE, BY CANDIDAL PARONYCHIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL HIV VACCINES MARKET SIZE, BY CANDIDAL PARONYCHIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL HIV VACCINES MARKET SIZE, BY CHRONIC PARONYCHIA, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL HIV VACCINES MARKET SIZE, BY CHRONIC PARONYCHIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL HIV VACCINES MARKET SIZE, BY CHRONIC PARONYCHIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL HIV VACCINES MARKET SIZE, BY PYOGENIC PARONYCHIA, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL HIV VACCINES MARKET SIZE, BY PYOGENIC PARONYCHIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL HIV VACCINES MARKET SIZE, BY PYOGENIC PARONYCHIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE VACCINES, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC VACCINES, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 52. CANADA HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 53. CANADA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 54. CANADA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 55. CANADA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 56. MEXICO HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 57. MEXICO HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 58. MEXICO HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 59. MEXICO HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 73. AUSTRALIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 74. CHINA HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 75. CHINA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 76. CHINA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 77. CHINA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 78. INDIA HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 79. INDIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 80. INDIA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 81. INDIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 86. JAPAN HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 87. JAPAN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 88. JAPAN HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 89. JAPAN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 90. MALAYSIA HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 91. MALAYSIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 94. PHILIPPINES HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 95. PHILIPPINES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 96. PHILIPPINES HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 98. SINGAPORE HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 99. SINGAPORE HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 100. SINGAPORE HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 102. SOUTH KOREA HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 103. SOUTH KOREA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 104. SOUTH KOREA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 105. SOUTH KOREA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 106. TAIWAN HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 107. TAIWAN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 108. TAIWAN HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 109. TAIWAN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 110. THAILAND HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 111. THAILAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 112. THAILAND HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 113. THAILAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 114. VIETNAM HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 115. VIETNAM HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 116. VIETNAM HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 117. VIETNAM HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 123. DENMARK HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 124. DENMARK HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 125. DENMARK HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 126. DENMARK HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 127. EGYPT HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 128. EGYPT HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 129. EGYPT HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 130. EGYPT HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 131. FINLAND HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 132. FINLAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 133. FINLAND HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 134. FINLAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 135. FRANCE HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 136. FRANCE HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 137. FRANCE HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 138. FRANCE HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 139. GERMANY HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 140. GERMANY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 141. GERMANY HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 142. GERMANY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 143. ISRAEL HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 144. ISRAEL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 145. ISRAEL HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 146. ISRAEL HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 147. ITALY HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 148. ITALY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 149. ITALY HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 150. ITALY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 151. NETHERLANDS HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 152. NETHERLANDS HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 153. NETHERLANDS HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 154. NETHERLANDS HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 155. NIGERIA HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 156. NIGERIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 157. NIGERIA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 158. NIGERIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 159. NORWAY HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 160. NORWAY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 161. NORWAY HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 162. NORWAY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 163. POLAND HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 164. POLAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 165. POLAND HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 166. POLAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 167. QATAR HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 168. QATAR HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 169. QATAR HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 170. QATAR HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 171. RUSSIA HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 172. RUSSIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 173. RUSSIA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 174. RUSSIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 179. SOUTH AFRICA HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 180. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 183. SPAIN HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 184. SPAIN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 185. SPAIN HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 186. SPAIN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 187. SWEDEN HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 188. SWEDEN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 189. SWEDEN HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 190. SWEDEN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 191. SWITZERLAND HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 192. SWITZERLAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 193. SWITZERLAND HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 194. SWITZERLAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 195. TURKEY HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 196. TURKEY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 197. TURKEY HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 198. TURKEY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 199. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 200. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 201. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 202. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 204. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 206. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
TABLE 207. GLOBAL HIV VACCINES MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 208. GLOBAL HIV VACCINES MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 209. GLOBAL HIV VACCINES MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 210. GLOBAL HIV VACCINES MARKET RANKING, BY KEY PLAYER, 2022
TABLE 211. GLOBAL HIV VACCINES MARKET SHARE, BY KEY PLAYER, 2022
TABLE 212. GLOBAL HIV VACCINES MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 213. GLOBAL HIV VACCINES MARKET MERGER & ACQUISITION
TABLE 214. GLOBAL HIV VACCINES MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 215. GLOBAL HIV VACCINES MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 216. GLOBAL HIV VACCINES MARKET INVESTMENT & FUNDING
TABLE 217. GLOBAL HIV VACCINES MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 218. GLOBAL HIV VACCINES MARKET: LICENSE & PRICING

Companies Mentioned

  • AlphaVax, Inc.
  • Antigen Express, Inc.
  • Argos Therapeutics, Inc.
  • Bionor Pharmaceuticals
  • Celldex Therapeutics, Inc.
  • Crucell N.V.
  • GeneCure LLC
  • Genetic Immunity, Inc.
  • GenVec, Inc.
  • GeoVax Labs, Inc.
  • GlaxoSmithKline plc
  • Immune Response BioPharma, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Novartis AG
  • Oncolys Biopharma
  • Profectus Biosciences
  • Sanofi SA
  • TVAX Biomedical

Methodology

Loading
LOADING...